bristol myers cobenfy news

Bristol Myers Gets US Nod for First New Schizophrenia Drug Type in Decades

Bristol Myers Squibb Co. gained US approval for the first new type of schizophrenia drug in seven decades, opening a fresh avenue of treatment for millions with the serious mental disorder.

Barron's on MSN · 9h

Bristol Myers Stock Jumps. Why FDA Approval for Its Schizophrenia Drug Is Groundbreaking.

Bristol Myers Squibb stock jumped after the pharma company won approval for its new schizophrenia drug late Thursday. “This drug takes the first new approach to schizophrenia treatment in decades,” the Food and Drug Administration said.

MM&M · 4h

Bristol Myers Squibb wins FDA approval for first new schizophrenia drug in 30 years

Cobenfy targets cholinergic receptors instead of the dopamine receptors long addressed in current schizophrenia drugs — a new treatment approach to the disease.

Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential

Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer ...

insurancebusinessmag11d

Bristol-Myers faces lawsuit over $2 billion pension risk transfer to Athene

Bristol-Myers Squibb Co is facing a class-action lawsuit related to a $2 billion pension risk transfer deal made five years ...

MarketWatch2d

2seventy, Bristol Myers Drop Abecma Study in Newly Diagnosed Patients

2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of their Abecma gene therapy in certain people newly diagnosed with the blood cancer multiple myeloma. 2seventy on ...

Coventry Telegraph5d

Man dies after falling from block of flats in Coventry

West Midlands Police, ambulance fire service staff were sent to the scene but unable to save the man A Coventry man has died after falling from the balcony of a tower block. Police were called to ...

Business Insider4d

Bristol-Myers Squibb: Hold Rating Justified by Market-Reflected Approval of KarXT Despite Promising Clinical Data

BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $48.00. Evan Seigerman has given his Hold rating due ...

2hon MSN

These Stocks Are Moving the Most Today: Bristol Myers, Costco, EchoStar, Cassava, Wynn, HP Inc., Acadia Healthcare, and More

Stocks traded mixed Friday after the Federal Reserve’s preferred inflation measure showed that consumer prices continue to ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results